Donepezil: a review

@article{Seltzer2005DonepezilAR,
  title={Donepezil: a review},
  author={B. Seltzer},
  journal={Expert Opinion on Drug Metabolism & Toxicology},
  year={2005},
  volume={1},
  pages={527 - 536}
}
  • B. Seltzer
  • Published 2005
  • Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer’s disease (AD). It has been shown to be of benefit in mild, moderate and severe stages of AD, vascular dementia and dementia associated with Parkinson’s disease. Donepezil is absorbed slowly, but completely, from the gut, reaching peak plasma levels in 3 – 4 h and, with daily dosing, steady-state concentration in 15 – 21 days. Within a relatively narrow range, there is a linear relationship between… Expand
61 Citations
Donepezil: an update
  • B. Seltzer
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2007
  • 69
Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease
  • 28
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
  • 191
Development of donepezil-induced hypokalemia following treatment of cognitive impairment
  • 1
  • PDF
Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease
  • 23
  • Highly Influenced
  • PDF
Donepezil: potential neuroprotective and disease-modifying effects
  • 19
Microglia signaling as a target of donepezil
  • 82
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 130 REFERENCES
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
  • E. Shintani, K. M. Uchida
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1997
  • 70
The pharmacology of donepezil: a new treatment of Alzheimer's disease.
  • 62
The safety and tolerability of donepezil in patients with Alzheimer's disease.
  • 74
Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses.
  • 59
  • PDF
Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer’s Disease
  • 87
Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil
  • 68
Regional Effects of Donepezil and Rivastigmine on Cortical Acetylcholinesterase Activity in Alzheimer’s Disease
  • 120
Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.
  • 78
...
1
2
3
4
5
...